Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
| Autor: | Kater, Arnon P., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James *, Owen, Carolyn, Assouline, Sarit E, Lamanna, Nicole, Robak, Tadeusz J. *, de la Serna, Javier *, Jaeger, Ulrich, Cartron, Guillaume *, Montillo, Marco, Mellink, Clemens *, Chyla, Brenda J., Wilson, Cameron *, Wu, Jenny *, Jiang, Yanwen *, Lefebure, Marcus *, Boyer, Michelle *, Seymour, John F. |
|---|---|
| Zdroj: | In Blood 5 November 2020 136 Supplement 1:19-21 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|